Clinical Trials Logo

Clinical Trial Summary

This is a Phase I, open-label, dose escalation study of LNP3794 (BI3011441) in subjects with NRAS/KRAS mutated advanced or metastatic refractory solid tumors. The purpose of this study is to evaluate the safety/tolerability, pharmacokinetic and pharmacodynamic profile of the orally administered LNP3794 (BI3011441) as monotherapy at selected dose levels.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05187858
Study type Interventional
Source Lupin Ltd.
Status Active, not recruiting
Phase Phase 1
Start date September 22, 2020
Completion date May 10, 2022